European Commission logo
English English
CORDIS - EU research results
CORDIS

Next generation decontamination: fast, effective, cheap and non-toxic

Project description

Bio-decontamination to prevent spread of infections in hospitals

The European Centre for Disease Prevention and Control estimates that 3.8 million people acquire a healthcare-associated infection each year in acute care hospitals in EU countries. Bio-decontamination is the best solution to prevent spreading of deadly bacteria or virus, eliminating 99.999 % of microorganisms. However, bio-decontamination is not widely adopted. The EU-funded DELOX project has developed an innovative decontamination agent based on a solid formulation – dryVHP – which releases hydrogen peroxide vapour at low temperatures (60° C). This property reduces power consumption, equipment cost and enables a more compact and robust device. The DELOX equipment is unique in the market as an affordable, compact and highly efficient solution.

Objective

Hospital acquired infections affect 1 in every 14 patients, a number that goes as high as 1 in every 5 patients when considering intensive care units. Delox has the potential to change that.
Decontamination is performed using several different methods and technologies nowadays. The most relevant one is sterilization, which is an expensive procedure, typically only affordable for very large hospital in well developed countries or outsourced to a specialized firm. In the laboratory and health context the use of Formaldehyde is also still frequent – because it is price competitive – but it is toxic and far from perfect.
The state-of-the-art technology is VHP (Vaporized Hydrogen Peroxide) which is costly, expensive and energy intensive, as it requires heating Hydrogen Peroxide to 130oC. Our formulation – dryVHP – differs by needing to be heat up to only 60 oC to produce the same effect. It is also significantly cheaper.
Delox will be initially brought to market for use in laboratory equipment (<2 m3) and then a more powerful and adjustable version will be launched to address the Hospital, clinics and food sectors.
It is the business outcome of more than 6 years of research and it has the potential to disrupt the bio-decontamination and sterilization market, having gathered interest from several large stakeholders, and received awards and recognition.
We have also already raised 371.8k€ from VC (300k), awards (10k), public startup vouchers (11k€) and the European Space Agency.
Within this Phase 1 we will prepare the next steps of our development (technical and commercial) but also validate our technology by preparing pilots with relevant players to demonstrate in real environment and prepare robust case studies that will boost market acceptance.
By bringing to the market a non-toxic bio-decontamination solution that is cheap, effective, rugged and non-toxic Delox will make bio-decontamination affordable and accessible everywhere.

Call for proposal

H2020-EIC-SMEInst-2018-2020

See other projects for this call

Sub call

H2020-SMEInst-2018-2020-1

Coordinator

DELOX - INVESTIGACAO, PROCESSOS E EQUIPAMENTOS CIENTIFICOS, LDA
Net EU contribution
€ 50 000,00
Address
TEC LABS CAMPUS DA FACULTADE DE CIENCIAS DA UNIVERSIDADE DE LISBOA, CAMPO GRANDE
1749-016 LISBOA
Portugal

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Continente Área Metropolitana de Lisboa Área Metropolitana de Lisboa
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 71 429,00